![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/AUROPHARMA.png)
Share the post "AUROBINDO PHARMA ‘s Q3 2024-25 Latest News: Revenue Rises by 8.53% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 8.53 % in the past year, substantial increase in net sales/revenue by 2.34 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -3.22 %, Marginal increase in other income during this quarter, up by 15.65%. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for AUROBINDO PHARMA LTD.. Profit dropped by -10.04 % Year to Year, AUROBINDO PHARMA LTD.’s profitability increased by 3.5 % in this quarter. 🔹 EPS over the Year and quarter: EPS declined by -9.23 % Year to Year. EPS increased by 4 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 7351.78 Cr | Rs. 7796.07 Cr | Rs. 7978.52 Cr | + 2.34 % | + 8.53 % |
| Expenses | Rs. 5753.06 Cr | Rs. 6229.93 Cr | Rs. 6400.54 Cr | + 2.74 % | + 11.25 % |
| Operating Profit | Rs. 1598.72 Cr | Rs. 1566.14 Cr | Rs. 1577.98 Cr | + 0.76 % | -1.3 % |
| OPM % | 21.75 % | 20.09 % | 19.78 % | -0.31 % | -1.97 % |
| Other Income | Rs. 162.52 Cr | Rs. 136 Cr | Rs. 157.29 Cr | + 15.65 % | -3.22 % |
| Interest | Rs. 75.55 Cr | Rs. 112.7 Cr | Rs. 118.48 Cr | + 5.13 % | + 56.82 % |
| Depreciation | Rs. 423.27 Cr | Rs. 382.28 Cr | Rs. 418.53 Cr | + 9.48 % | -1.12 % |
| Profit before tax | Rs. 1262.42 Cr | Rs. 1207.16 Cr | Rs. 1198.26 Cr | -0.74 % | -5.08 % |
| Tax % | 25.49 % | 32.35 % | 29.57 % | -2.78 % | + 4.08 % |
| Net Profit | Rs. 939.97 Cr | Rs. 816.95 Cr | Rs. 845.57 Cr | + 3.5 % | -10.04 % |
| EPS in Rs | Rs. 16.04 | Rs. 14 | Rs. 14.56 | + 4 % | -9.23 % |
Today, we’re looking at AUROBINDO PHARMA LTD.’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 8.53 %. However, it did see a marginal increase of 2.34 % from the previous quarter. Expenses ticked up slightly by 2.74 % quarter-on-quarter, aligning with the annual rise of 11.25 %. Operating profit, while down -1.3 % compared to last year, faced a quarter-on-quarter increase of 0.76 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.97 %, but a shrinkage of -0.31 % sequentially. Other income rose by 15.65 % compared to the last quarter, despite an annual decline of -3.22 %. Interest expenses surged remarkably by 5.13 % from the previous quarter, yet the year-over-year increase remains at a moderate 56.82 %. Depreciation costs climbed by 9.48 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -1.12 %. Profit before tax declined annually by -5.08 % but saw a reduction from the preceding quarter by -0.74 %.
Tax expenses as a percentage of profits increased slightly by 4.08 % compared to last year, with a more notable quarter-on-quarter decrease of -2.78 %. Net profit fell by -10.04 % year-on-year but experienced a 3.5 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -9.23 % but a quarterly rise of 4 %. In summary, AUROBINDO PHARMA LTD.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 7351.78 Cr | Rs. 7796.07 Cr | Rs. 7978.52 Cr | + 2.34 % | + 8.53 % |
| Expenses | Rs. 5753.06 Cr | Rs. 6229.93 Cr | Rs. 6400.54 Cr | + 2.74 % | + 11.25 % |
| Operating Profit | Rs. 1598.72 Cr | Rs. 1566.14 Cr | Rs. 1577.98 Cr | + 0.76 % | -1.3 % |
| Net Profit | Rs. 939.97 Cr | Rs. 816.95 Cr | Rs. 845.57 Cr | + 3.5 % | -10.04 % |
| EPS in Rs | Rs. 16.04 | Rs. 14 | Rs. 14.56 | + 4 % | -9.23 % |
In reviewing AUROBINDO PHARMA LTD.’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 8.53 % year-on-year growth, however, there was a minor increase of 2.34 % from the previous quarter. Expenses rose by 11.25 % compared to the previous year, with a 2.74 % increase quarter-on-quarter. Operating Profit dropped by -1.3 % annually, and saw a 0.76 % increase from the last quarter.
Net Profit showed yearly decrease of -10.04 %, and experienced a 3.5 % increase from the previous quarter. Earnings Per Share (EPS) fell by -9.23 % annually, however rose by 4 % compared to the last quarter. In essence, while AUROBINDO PHARMA LTD. faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SAREGAMA.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/MISHTANN.png)